Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Contrast Enhanced Mammography (CEM) to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

NCT05206331 is registered in ClinicalTrials.gov with Margarita Louise Zuley as lead sponsor.

NCT NCT05206331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05206331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Contrast Enhanced Mammography (CEM) to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
Lead sponsor
Margarita Louise Zuley
Phase
Phase 4
Overall status
Completed
Start date
February 1, 2022
Completion date
August 21, 2026
Enrollment
2,089 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer